Table 1 |
||||||
|
Mean response levels of the three CMV-responsive donors |
||||||
|
% CD3+CD8+ cells |
ELISPOT (peptide mix) |
CFC (peptide mix) |
CFC (pp65495–503) |
Tetramer (pp65495–503) |
ELISPOT (pp65495–503) |
|
|
|
||||||
|
Donor 41 (low) |
20.3% |
270 SFC1 [0.53%] |
nd2 |
0.06%2 |
0.06%2 |
8 SFC1 [0.02%] |
|
Donor 68 (med) |
12.1% |
285 SFC1 [0.94%] |
0.28%2 |
0.28%2 |
0.25%2 |
31 SFC1 [0.10%] |
|
Donor 43 (high) |
26.3% |
95 SFC1 [0.14%] |
0.87%2 |
0.93%2 |
1.27%2 |
28 SFC1 [0.04%] |
|
|
||||||
|
1 ELISPOT results reported as SFC per 2.5 × 105 PBMC. Numbers in brackets indicate the values when re-calculated as % of CD8+ T cells. Note that ELISPOT responses with peptide mix did not match the other assays in terms of low, medium, and high responders. 2 CFC and tetramer results reported as % of CD8+ T cells. nd = CFC was not done on this donor due to predicted very low response (0.02%) seen in pre-screening. |
||||||
|
Maecker et al. BMC Immunology 2008 9:9 doi:10.1186/1471-2172-9-9 |
||||||
